期刊
CURRENT OPINION IN INFECTIOUS DISEASES
卷 25, 期 5, 页码 564-569出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QCO.0b013e32835635df
关键词
AIDS; chronic hepatitis C; fibrosis; serum biomarkers; transient elastography
资金
- Instituto de Salud Carlos III [PI08/0738, PI11/00245, ISCIII-RETIC RD06/006, PI11/01556]
- Fundacion para la Investigacion y la Prevencion del Sida en Espana (FIPSE) [36443/03, 361020/10]
Purpose of review This review presents recent findings on noninvasive alternatives for the diagnosis of fibrosis and cirrhosis in patients who are coinfected with HIV and hepatitis C virus (HCV). Recent findings APRI, FIB-4, and Forns were accurate indices for the diagnosis of cirrhosis [area under the receiver operating characteristic curve (AUROC) >0.80] but not for the diagnosis of significant and advanced fibrosis (AUROC < 0.80). Diagnostic accuracy was affected by CD4(+) T-cell count and alanine aminotransferase levels. An artificial neural network to predict significant fibrosis was highly accurate (AUROC of 0.853), outperforming simple noninvasive indices. Derivations of the FibroMeter panel (FibroMeter(2G) HICV and FibroMeter(3G) HICV) achieved high diagnostic accuracy for significant fibrosis (AUROC of 0.823 and 0.833, respectively). Transient elastography had higher predictive accuracy than previously validated panels for diagnosis of advanced fibrosis (F > 3) and cirrhosis (0.93 and 0.99, respectively). However, misclassification as F >= 3 was more common among patients with steatosis than among those without steatosis (25 versus 5%, P = 0.01). Moreover, transient elastography can predict clinically significant and severe portal hypertension in HIV/HCV-coinfected patients. Summary Both biomarkers and transient elastography can accurately diagnose fibrosis and cirrhosis and are better at excluding than at predicting liver disease in HIV/HCV-coinfected patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据